Dedicated to Better Health 

The treatment or prevention of a disease through the administration of cells that have been selected, manipulated, or altered outside of the body, is defined as cell therapy.

We virtually sent our European Business Development Director Joanna Hay, as well as Business Development Associates Edward Thornton and Maciej Trybull to catch up with current and future partners in the Advanced Therapy Medicinal Product (ATMP) community and listen in on the exciting talks setting the direction of the industry.

Collaboration investigates enhanced manufacturing of AAV and lentiviral vectors to improve quality and productivity for gene therapy and vaccine developers

Albumedix Ltd., a recognized global leader in recombinant human albumin specializing in the enablement of advanced therapies, announces the completed expansion of the company’s commercial-scale manufacturing facility, alongside with the establishment of a new Technology Centre equipped with state-of-the-art laboratories at its UK-based campus in Nottingham.

Albumedix Ltd., an enabler of advanced therapies and world leader in recombinant human albumin, announced today that they have entered into a distribution agreement with established and well recognized reagent supplier FUJIFILM Wako Pure Chemical Corporation in Japan and China including Hong Kong.

It has now been three weeks since Albumedix´ US Business Development Director Brian Macdonald attended VSOHIO21

In a conversation with Alessandro Mantell from Mantell Associates, Jonas and Gregor are happy to join the list of previous podcast guests and share their experience of COVID-19 and how it has been adapting to life and business during the Global Pandemic.

Albumedix Ltd. (‘Albumedix’), an enabler of advanced therapies and the world leader in recombinant human albumin (rAlb), announced today that they have entered into a collaboration agreement with the Cell and Gene Therapy Catapult (CGT Catapult) to investigate the use of Albumedix´ proprietary albumin-based solutions for advanced therapy applications, including viral vectors manufacturing.

Already a month into the year 2021 and we are picking up where we left off, while looking forward to a year where we can get a bit more back to normal.

Did you know that unlike other recombinant human albumin manufacturers, Albumedix are so much more than simply ‘an albumin supplier’? When you work with us, you also get access to 100 brilliant minds behind the vial, including a dedicated Business Development Director responsible for managing your account.

Meet Dangerous Dave Phillipson; a formidable, Nottingham based, three-time Paralympian in tennis who took to the water in 2017 and is now paracanoeing his way to Tokyo 2021.

Meet Helen Rawsthorne. Helen is a Senior Research Scientist within Albumedix and a truly brilliant example of our many brilliant minds. Presently in her 7th year working for the company, the following interview will take you through Helen's background, her role within Albumedix and give you a sneak preview into what our Technical Group get up to in the day.

Albumedix are thrilled to be able to continue supporting the Nottinghamshire Wildlife Trust in their endeavours to protect and restore the beautiful environment and wildlife both on our doorstep and across the region.

Albumedix is a world leading manufacturer of recombinant human albumin (rHA), and as such our manufacturing plant is the core of our business. As a company, we talk a lot about our rHA products, how they’re useful in different applications and what benefits they can bring to final therapies for patients worldwide. However, we don’t talk as much about the amazing people within our business that make the magic happen.

In December, Albumedix held a 'Capping off Ceremony' to celebrate the brand new, four-storey manufacturing plant extension being confirmed as watertight!